<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27358067</article-id><article-id pub-id-type="pmc">4928349</article-id><article-id pub-id-type="publisher-id">194</article-id><article-id pub-id-type="doi">10.1186/s13195-016-0194-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yassine</surname><given-names>Hussein N.</given-names></name><address><phone>+1-323-442-1909</phone><fax>+1-323-442-2808</fax><email>hyassine@usc.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rawat</surname><given-names>Varun</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mack</surname><given-names>Wendy J.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Quinn</surname><given-names>Joseph F.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Yurko-Mauro</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Bailey-Hall</surname><given-names>Eileen</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Aisen</surname><given-names>Paul S.</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Chui</surname><given-names>Helena C.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>Lon S.</given-names></name><xref ref-type="aff" rid="Aff6"/><xref ref-type="aff" rid="Aff7"/></contrib><aff id="Aff1"><label/>Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA </aff><aff id="Aff2"><label/>Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA </aff><aff id="Aff3"><label/>Department of Neurology, Oregon Health &#x00026; Science University, and Portland VA Medical Center , Portland, OR USA </aff><aff id="Aff4"><label/>Clinical Research Department, DSM Nutritional Products, Columbia, MD USA </aff><aff id="Aff5"><label/>Alzheimer&#x02019;s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA </aff><aff id="Aff6"><label/>Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA </aff><aff id="Aff7"><label/>Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>8</volume><elocation-id>25</elocation-id><history><date date-type="received"><day>5</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Apolipoprotein E (<italic>APOE</italic>) &#x0025b;4 and low cerebrospinal fluid (CSF) amyloid-&#x003b2;42 (A&#x003b2;42) levels are predictors for developing Alzheimer&#x02019;s disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by <italic>APOE</italic> genotype. Our objective in the present study was to examine whether <italic>APOE</italic> &#x0025b;4 genotype and low CSF A&#x003b2;42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer&#x02019;s Disease Cooperative Study-sponsored DHA clinical trial.</p></sec><sec><title>Methods</title><p>Phospholipid DHA was assayed in&#x000a0;the plasma of 384 participants and CSF of 70 participants at baseline. Forty-four of the 70 participants completed the 18-month follow-up visit after allocation to placebo (<italic>n</italic>&#x02009;=&#x02009;15) or DHA (<italic>n</italic>&#x02009;=&#x02009;29). Plasma and CSF DHA levels, CSF A&#x003b2;42, Tau, and phosphorylated Tau were measured at baseline and after the 18-month intervention. Participants were divided into tertiles based on baseline A&#x003b2;42 CSF levels. To assess DHA delivery across the blood-brain barrier, the ratio of CSF to plasma DHA levels was calculated.</p></sec><sec><title>Results</title><p>At baseline, there were no significant differences between CSF or plasma phospholipid DHA levels by CSF A&#x003b2;42 tertiles or &#x0025b;4 status. After 18&#x000a0;months of DHA supplementation, participants at the lowest A&#x003b2;42 tertile had significantly lower CSF DHA levels (<italic>p</italic>&#x02009;=&#x02009;0.01) and lower CSF-to-plasma DHA ratios (<italic>p</italic>&#x02009;=&#x02009;0.05)&#x000a0;compared to the other tertiles. Baseline CSF A&#x003b2;42 levels were significantly lower in &#x0025b;4 carriers than in &#x0025b;4 noncarriers (<italic>p</italic>&#x02009;=&#x02009;0.01). Participants carrying the &#x0025b;4 allele (<italic>n</italic>&#x02009;=&#x02009;25) demonstrated a less pronounced increase in CSF DHA level compared with noncarriers (<italic>n</italic>&#x02009;=&#x02009;4), with a possible interaction effect between treatment and APOE genotype (<italic>p</italic>&#x02009;=&#x02009;0.07).</p></sec><sec><title>Conclusions</title><p>APOE &#x0025b;4 allele and lower CSF A&#x003b2;42 levels were associated with less transport of DHA to CSF. Brain amyloid pathology&#x000a0;may limit the delivery of DHA to the brain in AD.</p></sec><sec><title>Trial Registration</title><p>Clinicaltrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00440050">NCT00440050</ext-link>. Registered on 22 Feb 2007.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>APOE</italic></kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Cerebrospinal fluid</kwd><kwd>Amyloid</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K23HL107389</award-id><award-id>P50-AG05142-31</award-id><award-id>UO1-AG10483</award-id><principal-award-recipient><name><surname>Yassine</surname><given-names>Hussein N.</given-names></name><name><surname>Aisen</surname><given-names>Paul S.</given-names></name><name><surname>Chui</surname><given-names>Helena C.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000957</institution-id><institution>Alzheimer's Association</institution></institution-wrap></funding-source><award-id>NIRG-15-361854</award-id><principal-award-recipient><name><surname>Yassine</surname><given-names>Hussein N.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Among the genes associated with late-onset Alzheimer&#x02019;s disease (AD), the gene encoding for apolipoprotein E (<italic>APOE</italic>) &#x0025b;4 has the strongest correlation with disease onset [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. The &#x0025b;4 isoform is expressed in about 15&#x000a0;% of the general population. However, it is present in about 40&#x000a0;% of patients with AD. Individuals with one &#x0025b;4 allele have a 3- to 4-fold increased propensity toward developing AD, which increases to 12-fold for individuals homozygous for the &#x0025b;4 allele [<xref ref-type="bibr" rid="CR2">2</xref>]. Furthermore, <italic>APOE</italic> &#x0025b;4 has a similar effect on age of AD onset, with carriers of the &#x0025b;4 allele developing AD symptoms earlier than the &#x0025b;3 carriers. Conversely, individuals with the &#x0025b;2 allele have a lower risk of developing AD [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid (n-3 PUFA) is important for brain health, as humans may not produce enough of it de novo. DHA is required for maintenance of neuronal membranes, amyloid-&#x003b2; (A&#x003b2;) clearance, and modulation of inflammation [<xref ref-type="bibr" rid="CR4">4</xref>]. DHA is involved in a variety of physiological processes, including aging, memory formation, synaptic membrane function, photoreceptor biogenesis and function, and neuroprotection. The levels of plasma DHA correlate with brain DHA content [<xref ref-type="bibr" rid="CR5">5</xref>], and they are reduced in AD brains [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Despite a large number of observational studies linking DHA intake to cognitive health [<xref ref-type="bibr" rid="CR4">4</xref>], randomized controlled trials in which investigators tested the effect of DHA intake on cognitive function&#x000a0;presented conflicting results [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Several studies suggested that carriers and non-carriers of <italic>APOE</italic> &#x0025b;4 respond differently to DHA supplementation [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>], with little or no effect of DHA supplementation [<xref ref-type="bibr" rid="CR12">12</xref>] and no relationship between the omega-3 on erythrocyte membranes with measures of cognition [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] in &#x0025b;4 carriers with cognitive impairment.</p><p>DHA crosses the blood-brain barrier after supplementation, but little is known about the factors that regulate its delivery to the brain [<xref ref-type="bibr" rid="CR19">19</xref>]. A preclinical study in human APOE replacement mice demonstrated reduced delivery of <sup>14</sup>C -labeled DHA to the brain in the &#x0025b;4 compared with the &#x0025b;3 and &#x0025b;2 human&#x000a0;replacement mice [<xref ref-type="bibr" rid="CR20">20</xref>]. In a different study, Calon et al. measured cerebral uptake of <sup>14</sup>C-DHA in 3xTg-AD mice that are prone to brain amyloid deposition. Those investigators found a 25&#x000a0;% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) decrease of brain transport coefficients of <sup>14</sup>C-DHA in this model of AD compared with nontransgenic littermates [<xref ref-type="bibr" rid="CR21">21</xref>]. To our knowledge, researchers examined the effect of DHA supplementation on cerebrospinal fluid (CSF)&#x000a0;levels in humans&#x000a0;in only two studies. [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In one study by Freund-Levi et al., CSF DHA levels were increased after 6&#x000a0;months supplementation with 2.3&#x000a0;g/day of a combination of n-3 PUFA, but the effect of <italic>APOE</italic> genotype on CSF delivery of DHA was not assessed. In the other study, a randomized, placebo-controlled clinical trial sponsored by the Alzheimer&#x02019;s Disease Cooperative Study (ADCS), researchers tested the effect of 2&#x000a0;g/day of DHA supplementation on cognitive function in AD over the course of 18&#x000a0;months, and&#x000a0;reported a significant increase in CSF DHA after supplementation [<xref ref-type="bibr" rid="CR12">12</xref>]. The primary study outcomes were the Alzheimer&#x02019;s Disease Assessment Scale-Cognition (ADAS-cog) and Clinical Dementia Rating. Both cognitive scores did not improve after DHA supplementation [<xref ref-type="bibr" rid="CR12">12</xref>]. A preplanned secondary analysis of the ADCS-sponsored trial demonstrated cognitive improvements in both ADAS-cog and the Mini Mental State Examination (MMSE) in non-carriers of the <italic>APOE</italic> &#x0025b;4 allele. We hypothesized that carrying the <italic>APOE</italic> &#x0025b;4 allele and cerebral amyloidosis as indexed by lower CSF A&#x003b2;42 levels limit the delivery of DHA to the brain. Therefore, we assessed the amount of DHA in CSF after the intervention by <italic>APOE</italic> &#x0025b;4 genotype and baseline CSF A&#x003b2;42 levels in the placebo and treatment arms in this ADCS-sponsored DHA trial.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Overview</title><p>The data were obtained from a completed, randomized, double-blind, placebo-controlled trial that was sponsored by the ADCS, a consortium of academic medical centers and private AD clinics funded by the National Institute on Aging. Fifty-one U.S. centers participated in this trial after obtaining approval from their local institutional review boards.</p><p>Individuals with probable AD were eligible if (1) their MMSE score was between 14 and 26, (2) they were medically stable, (3) they consumed on average no more than 200&#x000a0;mg/day of DHA (as assessed by a brief 7-item food frequency questionnaire [<xref ref-type="bibr" rid="CR23">23</xref>]), and (4) they were not taking DHA or omega-3 fatty-acid supplements. A total of 384 of 402 study trial participants provided plasma for DHA measurements. Participants were randomly allocated to placebo or 2&#x000a0;g of DHA (supplied by DSM Nutritional Products, Columbia, MD, USA) and observed for 18&#x000a0;months. A total of 295 participants completed the trial while taking study medication (DHA group 171, placebo group 124). All participants without contraindications to CSF examination (e.g., anticoagulation) were invited to participate in the CSF study. In these individuals, lumbar puncture was performed the morning after an overnight fast at baseline and 18&#x000a0;months following randomization.</p><p>The study drug was an algae-derived DHA (DHASCO oil) obtained from DSM Nutritional Products, administered as four capsules, dosed as 1&#x000a0;g twice per day for a total daily dose of 2&#x000a0;g/day of DHA. DHASCO oil contains approximately 45&#x02013;55&#x000a0;% DHA by weight and does not contain eicosapentaenoic acid (EPA). The DHA dose was selected on the basis of evidence that plasma levels increase in a dose-dependent manner up to approximately 2&#x000a0;g/day, while at higher DHA doses no further increase in plasma DHA is observed [<xref ref-type="bibr" rid="CR24">24</xref>]. Placebo (corn/soy oil) capsules were identical in appearance.</p><p>In the fatty-acid analysis, plasma phospholipid fatty-acid levels were determined at DSM Nutritional Products using established methods [<xref ref-type="bibr" rid="CR24">24</xref>] with modifications for CSF analysis. Briefly, plasma total lipids were extracted from 400&#x000a0;&#x003bc;l of plasma using the methods of Folch et al. [<xref ref-type="bibr" rid="CR25">25</xref>]. The plasma phospholipids were isolated by thin-layer chromatography using 60/40/3 vol/vol/vol hexane/ether/acetic acid on 20&#x02009;&#x000d7;&#x02009;20 silica gel 60 plates with 250-&#x003bc;m thickness. CSF total lipids were extracted from 4&#x000a0;ml of CSF, also using the methods of Folch et al. Tricosanoic free fatty acid (23:0) was added to each sample as an internal standard. The plasma phospholipids and CSF total lipids were saponified with 0.5&#x000a0;N methanolic sodium hydroxide, and the fatty acids were converted to methyl esters with 14&#x000a0;% boron trifluoride/methanol at 100&#x000a0;&#x000b0;C for 30&#x000a0;minutes [<xref ref-type="bibr" rid="CR26">26</xref>]. Fatty-acid methyl esters were analyzed by gas-liquid chromatography using a Hewlett Packard 6890 chromatograph (Agilent Technologies, Santa Clara, CA, USA) equipped with a flame ionization detector. The fatty-acid methyl esters were separated on a 30-m FAMEWAX capillary column (0.25-mm diameter, 0.25-&#x003bc;m coating thickness; Restek, Bellefonte, PA, USA) using hydrogen at a flow rate of 2.1&#x000a0;ml/minute. The chromatographic run parameters included an oven starting temperature of 130&#x000a0;&#x000b0;C that was increased at a rate of 6&#x000a0;&#x000b0;C/minute to 225&#x000a0;&#x000b0;C, where it was held for 20&#x000a0;minutes before being increased to 250&#x000a0;&#x000b0;C at a rate of 15&#x000a0;&#x000b0;C/minute, with a final hold of 5&#x000a0;minutes. The injector and detector temperatures were constant at 220&#x000a0;&#x000b0;C and 230&#x000a0;&#x000b0;C, respectively. Plasma phospholipids were run at a 48:1 split flow, and the CSF total lipids were run at a 20:1 split flow. Peaks were identified by comparison of retention times with external fatty-acid methyl ester standard mixtures obtained from Nu-Chek Prep (Elysian, MN, USA). The fatty-acid profiles were expressed as a percentage of the total fatty acid in micrograms (weight percent). <italic>APOE</italic> genotype was assessed in the research laboratory. A&#x003b2;42 and Tau in the CSF were measured by using a dual-antibody sandwich enzyme-linked immunosorbent assay [<xref ref-type="bibr" rid="CR27">27</xref>] at the University of Pennsylvania Research Lab.</p></sec><sec id="Sec4"><title>Statistical analysis</title><p>Mean (SD) or median (25th&#x02013;75th percentile range) values for non-normally distributed data were computed. The study group was divided into tertiles based on CSF A&#x003b2;42 levels at baseline. The ratio of CSF to plasma DHA was calculated as an index of DHA transport across the blood-brain barrier. The dependent variables were (1)18 months CSF and plasma phospholipid DHA levels, (2) ratio of CSF to plasma DHA levels&#x000a0;at 18 months, and (3) the difference in DHA levels in CSF and plasma phospholipid at baseline and 18&#x000a0;months after supplementation. The independent variables were A&#x003b2; group (tertiles), treatment group, <italic>APOE</italic> genotype, and the interaction between the treatment group and <italic>APOE</italic> genotype using a linear regression model. Pearson or Spearman correlation tests were used to correlate the variables. Baseline plasma phospholipid and CSF DHA levels&#x000a0;by <italic>APOE</italic> groups were explained by a linear regression model. Linear modeling was also used to explain the relationship of baseline measures of CSF A&#x003b2;42 (independent variable) with the 18-month change in CSF DHA (dependent variable); this analysis was adjusted for baseline CSF DHA and <italic>APOE</italic> genotype. Significance was defined as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. The data were analyzed using the program R version 3.2.3.</p></sec></sec><sec id="Sec5"><title>Results</title><p>Plasma (<italic>n</italic>&#x02009;=&#x02009;384) and CSF samples (<italic>n</italic>&#x02009;=&#x02009;70) from participants in this ADCS trial were assayed for DHA levels at the baseline visit. The 70 participants who consented to lumbar puncture included carriers of &#x0025b;2/&#x0025b;3 (<italic>n</italic>&#x02009;=&#x02009;2), &#x0025b;2/&#x0025b;4 (<italic>n</italic>&#x02009;=&#x02009;1), &#x0025b;3/&#x0025b;3 (<italic>n</italic>&#x02009;=&#x02009;16), &#x0025b;3/&#x0025b;4 (<italic>n</italic>&#x02009;=&#x02009;32), and &#x0025b;4/&#x0025b;4 (<italic>n</italic>&#x02009;=&#x02009;19). Forty-four of the 70 CSF substudy participants completed the second lumbar puncture at the 18-month visit after allocation to either the placebo (<italic>n</italic>&#x02009;=&#x02009;15) or DHA (<italic>n</italic>&#x02009;=&#x02009;29) treatment group. Among those allocated to DHA were carriers of &#x0025b;3/&#x0025b;3 (<italic>n</italic>&#x02009;=&#x02009;4), &#x0025b;3/&#x0025b;4 (<italic>n</italic>&#x02009;=&#x02009;17), and &#x0025b;4/&#x0025b;4 (<italic>n</italic>&#x02009;=&#x02009;7), and one participant carried the &#x0025b;2/&#x0025b;4 allele. Baseline levels of plasma phospholipid&#x000a0;DHA (<italic>n</italic>&#x02009;=&#x02009;384, <italic>p</italic>&#x02009;=&#x02009;0.61) and&#x000a0;total CSF DHA (<italic>n</italic>&#x02009;=&#x02009;70,&#x000a0;<italic>p</italic>&#x02009;=&#x02009;0.44) did not differ between <italic>APOE</italic> &#x0025b;4 carriers and noncarriers. The distribution of baseline CSF DHA levels and plasma phospholipid DHA levels, as well as the ratio of CSF to plasma DHA, in all 70 participants is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. These findings indicated that plasma phospholipid DHA (<italic>p</italic>&#x02009;=&#x02009;0.8) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>) and CSF DHA (<italic>p</italic>&#x02009;=&#x02009;0.7) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>) did not differ by <italic>APOE</italic> genotype at baseline. The ratio of CSF to plasma DHA was significantly different among the <italic>APOE</italic> genotype groups (<italic>p</italic>&#x02009;=&#x02009;0.03 for groupwise comparison) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>), with the largest differences apparent between &#x0025b;2 carriers and &#x0025b;4 homozygotes. However, the significance of this&#x000a0;finding is limited by the small number of &#x0025b;2 carriers in this group (<italic>n</italic>&#x02009;=&#x02009;3). Baseline CSF and plasma DHA levels were significantly correlated (<italic>r</italic>&#x02009;=&#x02009;0.3, <italic>p</italic>&#x02009;=&#x02009;0.01); this correlation did not differ by &#x0025b;4 status. Of the 70 participants, 44 had measurements of CSF A&#x003b2;42. <italic>APOE</italic> &#x0025b;4 carriers had lower CSF A&#x003b2;42 levels compared with non-carriers (<italic>p</italic>&#x02009;=&#x02009;0.01) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Baseline CSF DHA levels by <italic>APOE</italic> status. The distributions of baseline plasma phospholipid and CSF DHA, as well as the ratio of CSF to plasma DHA, are demonstrated by <italic>APOE</italic> genotype (<italic>n</italic>&#x02009;=&#x02009;70). There were no significant differences in (<bold>a</bold>) plasma phospholipid or (<bold>b</bold>) CSF DHA levels by <italic>APOE</italic> genotype. <bold>c</bold> The ratio of CSF to plasma DHA by <italic>APOE</italic> genotype at baseline significantly differed between the <italic>APOE</italic> genotype groups (<italic>p</italic>&#x02009;=&#x02009;0.03 for group comparison). <bold>d</bold> CSF A&#x003b2;42 levels were significantly lower in &#x0025b;4 carriers at baseline (<italic>p</italic>&#x02009;=&#x02009;0.01 for group comparison). DHA levels are reported as a percentage by weight. The groups were compared using linear regression with DHA level or CSF-to-plasma DHA ratio as the dependent variable and groups as the covariate.*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for group comparison. <italic>A&#x003b2;42</italic> amyloid-&#x003b2;42, <italic>APOE</italic> apolipoprotein E, <italic>CSF</italic> cerebrospinal fluid, <italic>DHA</italic> docosahexaenoic acid, <italic>PL&#x000a0;Phospholipids</italic>
</p></caption><graphic xlink:href="13195_2016_194_Fig1_HTML" id="MO1"/></fig></p><p>To understand the effect of baseline CSF A&#x003b2;42 levels on DHA levels, the study group was divided into CSF A&#x003b2;42 tertiles (T1&#x02009;=&#x02009;A&#x003b2;42 levels &#x0003c;147&#x000a0;pg/ml, T2&#x02009;=&#x02009;A&#x003b2;42 levels between 147 and 174&#x000a0;pg/ml, T3&#x02009;=&#x02009;A&#x003b2;42 levels &#x0003e;174&#x000a0;pg/ml). At baseline, plasma phospholipid or CSF DHA did not differ between the groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref> and <xref rid="Fig2" ref-type="fig">b</xref>). The participants at the lowest tertile of CSF A&#x003b2;42 had lower mean CSF-to-plasma DHA ratios than the other two groups; however, this difference did not reach statistical significance (<italic>p</italic>&#x02009;=&#x02009;0.15 for three-way group comparison, <italic>p</italic>&#x02009;=&#x02009;0.19 for difference between T1 and T2, and <italic>p</italic>&#x02009;=&#x02009;0.06 for difference between T1 and T3) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Baseline plasma phospholipid and CSF DHA levels by CSF A&#x003b2;42 tertiles. Baseline phospholipid and CSF DHA measurements were compared in three groups of participants based on CSF A&#x003b2;42 tertiles at baseline (<italic>n</italic>&#x02009;=&#x02009;44, T1&#x02009;=&#x02009;A&#x003b2;42 levels &#x0003c;147&#x000a0;pg/ml, T2&#x02009;=&#x02009;A&#x003b2;42 levels between 147 and 174&#x000a0;pg/ml, and T3&#x02009;=&#x02009;A&#x003b2;42 levels &#x0003e;174&#x000a0;pg/ml). The ratio of CSF to plasma DHA was calculated as an index of DHA transport across the blood-brain barrier (<bold>a</bold> and <bold>b</bold>). There was no significant difference in plasma phospholipid of CSF DHA by A&#x003b2;42 tertiles at baseline. <bold>c</bold> A trend was observed for lower baseline CSF to plasma DHA (<italic>p</italic>&#x02009;=&#x02009;0.15 for three-way group comparison, <italic>p</italic>&#x02009;=&#x02009;0.19 for difference between T1 and T2, and <italic>p</italic>&#x02009;=&#x02009;0.06 for difference between T1 and T3) in the lowest tertile of A&#x003b2;42. <italic>A&#x003b2;42</italic> amyloid-&#x003b2;42, <italic>CSF</italic> cerebrospinal fluid, <italic>DHA</italic> docosahexaenoic acid</p></caption><graphic xlink:href="13195_2016_194_Fig2_HTML" id="MO2"/></fig></p><p>Plasma phospholipid DHA was assessed in 195 DHA-treated participants at baseline and 18&#x000a0;months following DHA supplementation. Among the 195, 119 carried the &#x0025b;4 allele and 76 were &#x0025b;4 noncarriers. A 300&#x000a0;% increase in plasma phospholipid DHA was observed (from 3.18 weight percentage at baseline to 9.82 weight percentage at 18&#x000a0;months; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). CSF DHA was assessed in 44 participants at baseline and 18&#x000a0;months. The increase in plasma DHA level was greater than the increase in CSF DHA. A 38&#x000a0;% increase in DHA CSF levels was observed in participants in the DHA treatment group (2.53 weight percentage at baseline and 3.46 weight percentage at 18&#x000a0;months; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). In participants allocated to DHA (<italic>n</italic>&#x02009;=&#x02009;29), the change in DHA levels from baseline to 18&#x000a0;months in CSF significantly correlated with the 18-month change in plasma (<italic>r</italic>&#x02009;=&#x02009;0.61, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p>Participants at the lowest tertile of A&#x003b2;42 had significantly lower mean CSF DHA levels after supplementation (<italic>p</italic>&#x02009;=&#x02009;0.01 for three-way group comparison, <italic>p</italic>&#x02009;=&#x02009;0.01 for difference between T1 and T2, and <italic>p</italic>&#x02009;=&#x02009;0.007 for difference between T1 and T3) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). The differences in CSF DHA levels among the A&#x003b2;42 groups at 18&#x000a0;months persisted after adjusting for <italic>APOE</italic> genotype (<italic>p</italic>&#x02009;=&#x02009;0.03 for three-way group comparison). In contrast, there was no significant difference in plasma DHA levels after supplementation by A&#x003b2;42 tertiles (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). The ratio of CSF to plasma DHA ratio was significantly lower after 18&#x000a0;months of DHA supplementation in participants at the lowest tertile of A&#x003b2;42 (<italic>p</italic>&#x02009;=&#x02009;0.054 for three-way group comparison, <italic>p</italic>&#x02009;=&#x02009;0.05 for difference between T1 and T2, and <italic>p</italic>&#x02009;=&#x02009;0.03 for difference between T1 and T3) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>). When CSF A&#x003b2;42 was analyzed as a continuous variable, CSF A&#x003b2;42 levels at baseline were associated with the 18-month change in CSF DHA (<italic>r</italic>&#x02009;=&#x02009;0.37, <italic>p</italic>&#x02009;=&#x02009;0.05) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). This relationship remained significant after we adjusted for baseline DHA levels (<italic>p</italic>&#x02009;=&#x02009;0.037) but was attenuated after we excluded the two CSF A&#x003b2;42 values greater than 250&#x000a0;pg/ml (<italic>r</italic>&#x02009;=&#x02009;0.35, <italic>p</italic>&#x02009;=&#x02009;0.07). After adjusting these models for <italic>APOE</italic> genotype, we found that the relationship of the 18-month change in DHA and baseline A&#x003b2;42 levels became less significant (<italic>p</italic>&#x02009;=&#x02009;0.1).<fig id="Fig3"><label>Fig. 3</label><caption><p>Plasma phospholipid and CSF DHA at 18&#x000a0;months. The distribution of phospholipid and CSF DHA measurements at 18&#x000a0;months by baseline CSF A&#x003b2;42 tertiles in participants allocated to DHA (<italic>n</italic>&#x02009;=&#x02009;29) is illustrated. <bold>a</bold> There was no significant difference in plasma phospholipid DHA by A&#x003b2;42 tertiles after 18&#x000a0;months of DHA. <bold>b</bold> and <bold>c</bold> After 18&#x000a0;months of DHA supplementation, there was a significant decrease in CSF DHA levels in&#x000a0;participants in the the first A&#x003b2;42 tertile (<italic>p</italic>&#x02009;=&#x02009;0.01 for three-way group comparison, <italic>p</italic>&#x02009;=&#x02009;0.01 for difference between T1 and T2, and <italic>p</italic>&#x02009;=&#x02009;0.007 for difference between T1 and T3) and a significantly lower increase in the CSF-to-plasma DHA ratio (<italic>p</italic>&#x02009;=&#x02009;0.05 for three-way group comparison, <italic>p</italic>&#x02009;=&#x02009;0.05 for difference between T1 and T2, and <italic>p</italic>&#x02009;=&#x02009;0.03 for difference between T1 and T3). The groups were compared using a linear regression model. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 for group comparison. <italic>A&#x003b2;42</italic> amyloid-&#x003b2;42, <italic>CSF</italic> cerebrospinal fluid, <italic>DHA</italic> docosahexaenoic acid</p></caption><graphic xlink:href="13195_2016_194_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Association of CSF A&#x003b2;42 with the change in CSF DHA. Baseline CSF A&#x003b2;42 was significantly associated with the change in CSF DHA after supplementation (<italic>r</italic>&#x02009;=&#x02009;0.37, <italic>p</italic>&#x02009;=&#x02009;0.05). The change in DHA was calculated as the difference between 18-month CSF DHA levels and the levels at baseline. The correlation was obtained using Spearman&#x02019;s correlation test. <italic>A&#x003b2;42</italic> amyloid-&#x003b2;42, <italic>CSF</italic> cerebrospinal fluid, <italic>DHA</italic> docosahexaenoic acid</p></caption><graphic xlink:href="13195_2016_194_Fig4_HTML" id="MO4"/></fig></p><p>There was a suggestion that <italic>APOE</italic> &#x0025b;4 status modified the DHA effect on the 18-month change in CSF, but not plasma phospholipid DHA levels. The 18&#x000a0;months, the increase in plasma phospholipid DHA did not differ by <italic>APOE</italic> &#x0025b;4 allele (<italic>p</italic>&#x02009;=&#x02009;0.8). In contrast, a possible interaction between <italic>APOE</italic> genotype and treatment at the 18-month time point in CSF DHA (<italic>p</italic>&#x02009;=&#x02009;0.07) was observed (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). In the DHA treatment group, over 18&#x000a0;months, the &#x0025b;4 noncarriers&#x02019; DHA levels increased by 68&#x000a0;%, whereas the &#x0025b;4 carriers&#x02019; CSF DHA levels increased by 37&#x000a0;% (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). All four &#x0025b;4 noncarriers showed increased CSF DHA levels after allocation to DHA treatment. In contrast, 6 of 25 &#x0025b;4 carriers did not have increased CSF DHA levels after supplementation. Tau and phosphorylated Tau (p-Tau) levels in the CSF did not differ between carriers and noncarriers of the &#x0025b;4 allele. Allocation to DHA treatment did not alter the decline in CSF A&#x003b2;42 or the change in Tau or p-Tau compared with placebo. Additional information on CSF DHA, A&#x003b2;42, Tau, and p-Tau by treatment group is summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig5"><label>Fig. 5</label><caption><p>Change in CSF DHA by <italic>APOE</italic> status and treatment arm. The effect of DHA treatment vs. placebo on CSF DHA levels by <italic>APOE</italic> genotype is illustrated. The increases in DHA levels in the CSF were less pronounced in carriers of the &#x0025b;4 allele. All &#x0025b;4 noncarriers had increased CSF DHA levels after allocation to DHA treatment. In contrast, 6 of the 25 &#x0025b;4 carriers did not increase DHA levels after DHA supplementation. There was a suggestion for an interaction effect between <italic>APOE</italic> genotype and treatment arm on CSF DHA levels (<italic>p</italic>&#x02009;=&#x02009;0.07). The data were modeled using multivariate linear regression with the change in CSF DHA as the dependent variable and <italic>APOE</italic> and treatment arm as the independent variables. <italic>A&#x003b2;42</italic> amyloid-&#x003b2;42, <italic>APOE</italic> apolipoprotein E, <italic>CSF</italic> cerebrospinal fluid, <italic>DHA</italic> docosahexaenoic acid</p></caption><graphic xlink:href="13195_2016_194_Fig5_HTML" id="MO5"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Eighteen-month changes with docosahexaenoic acid or placebo treatment by apolipoprotein E &#x003b5;4 status&#x000a0;on CSF DHA, A&#x003b2;42, Tau and p-Tau levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">DHA treated, <italic>APOE</italic> &#x0025b;4 non-carriers (<italic>n</italic>&#x02009;=&#x02009;4)</th><th colspan="2">Placebo&#x000a0;treated, <italic>APOE</italic> &#x0025b;4 non-carriers (<italic>n</italic>&#x02009;=&#x02009;4)</th><th colspan="2">DHA treated, <italic>APOE</italic> &#x0025b;4 carriers (<italic>n</italic>&#x02009;=&#x02009;25)</th><th colspan="2">Placebo&#x000a0;treated, <italic>APOE</italic> &#x0025b;4 carriers (<italic>n</italic>&#x02009;=&#x02009;11)</th></tr><tr><th/><th>Baseline</th><th>18&#x000a0;months</th><th>Baseline</th><th>18&#x000a0;months</th><th>Baseline</th><th>18&#x000a0;months</th><th>Baseline</th><th>18&#x000a0;months</th></tr></thead><tbody><tr><td>DHA,<sup>a</sup> % by weight</td><td>2.21 (0.44)</td><td>3.71 (0.71)</td><td>2.66 (0.81)</td><td>1.95 (0.28)</td><td>2.46 (0.59)</td><td>3.38 (0.90)</td><td>2.28 (0.6)</td><td>2.18 (0.50)</td></tr><tr><td>A&#x003b2;42, pg/ml</td><td>208 (55)</td><td>189 (51)</td><td>190 (36)</td><td>183 (36)</td><td>150 (30)</td><td>140 (30)</td><td>151 (35)</td><td>145 (33)</td></tr><tr><td>Tau, pg/ml</td><td>120 (110)</td><td>121 (125)</td><td>118 (42)</td><td>129 (35)</td><td>112 (53)</td><td>108 (136)</td><td>133 (94)</td><td>126 (88)</td></tr><tr><td>p-Tau,<sup>b</sup> pg/ml</td><td>39 (43)</td><td>40 (43)</td><td>47 (23)</td><td>53 (28)</td><td>47 (18)</td><td>44 (17)</td><td>53 (37)</td><td>51(33)</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations: A&#x003b2;42</italic> amyloid-&#x003b2;42, <italic>APOE</italic> apolipoprotein E, <italic>CSF</italic> cerebrospinal fluid, <italic>DHA</italic> docosahexaenoic acid, <italic>p-Tau</italic> phosphorylated Tau</p><p>Data are presented as mean (SD). Two-way analysis of variance was used to compare placebo and treatment groups by genotype</p><p>
<sup>a</sup>
<italic>p</italic>&#x02009;=&#x02009;0.07 for an interaction between treatment arm and <italic>APOE</italic> genotype</p><p>
<sup>b</sup>
<italic>p</italic>&#x02009;=&#x02009;0.04 for the difference in p-Tau by <italic>APOE</italic> groups</p></table-wrap-foot></table-wrap></p><p>DHA treatment changed the percentage of CSF arachidonic acid (AA). We observed a significant decrease in CSF AA in participants assigned to DHA treatment compared with placebo (change in DHA vs. placebo &#x02212;2.27 vs. &#x02212;0.64, <italic>p</italic>&#x02009;=&#x02009;0.002). The 18-month change in AA did not correlate with the 18-month change in CSF A&#x003b2;42 or CSF Tau/p-Tau, and it did not differ by <italic>APOE</italic> group. A previous study indicated that DHA supplementation was associated with decreases in AA transport to the brain [<xref ref-type="bibr" rid="CR22">22</xref>]. Brain AA uptake determined by positron emission tomography is increased in people with AD [<xref ref-type="bibr" rid="CR28">28</xref>], and AA is a precursor for inflammatory mediators [<xref ref-type="bibr" rid="CR29">29</xref>]. The change in CSF EPA did not differ between the placebo and treatment arms in the present study (<italic>p</italic>&#x02009;=&#x02009;0.2). The change in CSF EPA by <italic>APOE</italic> groups at baseline and after DHA supplementation did not reach statistical significance (<italic>p</italic>&#x02009;=&#x02009;0.13). These findings were expected, as the DHA product we used did not contain EPA.</p></sec><sec id="Sec6"><title>Discussion</title><p>The main finding of the ADCS-sponsored DHA trial was that the allocation to DHA treatment did not influence the rate of cognitive decline in patients with dementia [<xref ref-type="bibr" rid="CR12">12</xref>]. A secondary analysis suggested benefit in ADAS-cog scores in noncarriers of the &#x0025b;4 genotype [<xref ref-type="bibr" rid="CR12">12</xref>]. We hypothesized that the DHA-associated cognitive improvement in &#x0025b;4 noncarriers could be related to greater CSF DHA delivery. Our hypothesis was based on two recent findings in human &#x0025b;4 allele&#x000a0;replacement mice [<xref ref-type="bibr" rid="CR20">20</xref>] and 3xTg-AD transgenic mouse models with brain amyloid deposition [<xref ref-type="bibr" rid="CR21">21</xref>] demonstrating less delivery of <sup>14</sup>C&#x000a0;labeled DHA across the blood-brain barrier compared with &#x0025b;4 non-carriers or littermate controls, respectively. The results of the present analysis suggest that (1) individuals with lower pretreatment CSF A&#x003b2;42 (both &#x0025b;4 carriers and &#x0025b;4 non-carriers) had reduced CSF DHA levels after supplementation, and (2) carriers of the &#x0025b;4 allele had less pronounced increases in CSF DHA levels following DHA treatment compared with &#x0025b;4 non-carriers. Therefore, it is possible that the lack of cognitive effect of DHA in this study was a result of poor brain delivery in participants with brain amyloid pathology and in those carrying the <italic>APOE</italic> &#x0025b;4 allele.</p><p>The major limitation of this study was the small number of &#x0025b;4 noncarriers (<italic>n</italic>&#x02009;=&#x02009;4). However, the differences in CSF DHA response between carriers and noncarriers of the <italic>APOE</italic> &#x0025b;4 allele may also be represented by the lower CSF A&#x003b2;42 levels observed in &#x0025b;4 carriers. Taken together, our results support the concept that the diminished response in the <italic>APOE</italic> &#x0025b;4 carriers could be the result of more severe disease with significant brain amyloidosis.</p><p>The results of our study suggest an effect of CSF A&#x003b2;42 on baseline CSF DHA levels and CSF-to-plasma DHA ratio. We observed 25&#x000a0;% lower CSF-to-plasma DHA ratio between the first and third tertiles of CSF A&#x003b2;42. This observation did not reach statistical significance, likely due to the small sample size (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). After the DHA intervention, however, these differences in CSF DHA levels by CSF A&#x003b2;42 groups were significant. The advantage of the DHA intervention is that it reduces variation resulting from potential confounders with baseline measurements (such as differences in seafood consumption or supplement use before the study) and provides a uniform dose of DHA supplementation using a controlled study design. The lower CSF-to-plasma DHA ratio in participants with lower CSF A&#x003b2;42 levels suggests a defect in DHA transport to the brain in AD.</p><p>One potential mechanism for these findings includes activation of phospholipase A<sub>2</sub> (PLA<sub>2</sub>). Upon entry into the brain, DHA is trapped by long-chain fatty-acid coenzyme A synthase activity, thereby facilitating its targeting to specific lipid pools, where it is esterified to phospholipid membranes [<xref ref-type="bibr" rid="CR30">30</xref>]. In the adult brain, DHA is no longer accreted (<italic>accretion</italic> refers to accumulation of DHA during development [<xref ref-type="bibr" rid="CR31">31</xref>]), and plasma DHA replaces brain consumption [<xref ref-type="bibr" rid="CR32">32</xref>]. DHA is esterified to phospholipids at the sn-2 position and deesterified by PLA<sub>2</sub>. Brain DHA is highly conserved, but at an energy cost [<xref ref-type="bibr" rid="CR33">33</xref>]. Upon release by PLA<sub>2</sub> activity, DHA is immediately reesterified into brain phospholipids. A decrease in both nonesterified DHA and total DHA in the CSF is observed in mild cognitive impairment and AD, as compared with cognitively healthy participants, and is associated with increased PLA<sub>2</sub> activity [<xref ref-type="bibr" rid="CR34">34</xref>]. PLA<sub>2</sub> is a complex family of phospholipases that include calcium-independent phospholipase A<sub>2</sub> and calcium-dependent phospholipase A<sub>2</sub> (cPLA<sub>2</sub>). cPLA<sub>2</sub> can target DHA, AA, and other lipids (such as plasmalogens). Several lines of evidence suggest that calcium-dependent signaling pathways are dysregulated in the neurons of hAPP (amyloidosis-prone) mice, particularly in the hippocampus [<xref ref-type="bibr" rid="CR35">35</xref>]. We hypothesize that amyloid pathology induces the activity of cPLA<sub>2</sub> [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] in AD brain regions, reducing brain DHA consumption through liberation of free DHA from CSF and brain phospholipids [<xref ref-type="bibr" rid="CR38">38</xref>]. These changes have significant implications for AD pathology, as DHA is critical in hippocampal neuronal development and synaptic function [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>The effect of <italic>APOE</italic> genotype on peripheral DHA metabolism is not clear. One study demonstrated a less pronounced increase in DHA associated with triglyceride or cholesterol ester after 6&#x000a0;weeks of DHA&#x02009;+&#x02009;EPA supplementation in &#x003b5;4 carriers vs. noncarriers [<xref ref-type="bibr" rid="CR40">40</xref>]. However, changes in DHA associated with triglyceride-rich particles by <italic>APOE</italic> genotype were not observed in the SATgen&#x003b5; study [<xref ref-type="bibr" rid="CR41">41</xref>]. Our results did not reveal that plasma phospholipid DHA levels differed by <italic>APOE</italic> &#x0025b;4 status at baseline or following DHA supplementation. In a population study with a larger sample size (<italic>n</italic>&#x02009;=&#x02009;1135), however, greater fish consumption was associated with greater increases in plasma phospholipid DHA only in &#x0025b;4 noncarriers [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>There is evidence in several studies other than the ADCS-sponsored DHA trial [<xref ref-type="bibr" rid="CR12">12</xref>] that the <italic>APOE</italic> &#x0025b;4 allele can modulate the response to DHA supplementation. In an Alzheimer&#x02019;s Disease Neuroimaging Initiative study that included cognitively healthy persons, patients with mild cognitive impairment, and patients with AD, the association of fish oil with ADAS-cog and brain volume was observed only in &#x0025b;4-negative patients [<xref ref-type="bibr" rid="CR16">16</xref>]. In 2005, Huang et al. [<xref ref-type="bibr" rid="CR17">17</xref>] examined fish oil use in the Cardiovascular Health Cognition Study (<italic>n</italic>&#x02009;=&#x02009;2233) among participants who developed dementia after several years of follow-up. Their study demonstrated that <italic>APOE</italic> status was an important determinant in modulating the effect of n-3 intake on cognitive status, with only &#x0025b;4 non-carriers being responsive to n-3 intake. In another longitudinal study, Whalley et al. reported a stronger association of red blood cell n-3 index with cognitive scores in &#x0025b;4 non-carriers compared with carriers [<xref ref-type="bibr" rid="CR18">18</xref>]. In contrast, three studies of participants without AD (Bordeaux sample of the three-city study [1999&#x02013;2006, <italic>n</italic>&#x02009;=&#x02009;1228] [<xref ref-type="bibr" rid="CR43">43</xref>], Chicago Health and Aging Project [1993&#x02013;2000, <italic>n</italic>&#x02009;=&#x02009;818] [<xref ref-type="bibr" rid="CR44">44</xref>], and the Memory and Aging Project clinical neuropathological cohort study [2004&#x02013;2013, <italic>n</italic>&#x02009;=&#x02009;286] [<xref ref-type="bibr" rid="CR45">45</xref>]) suggest cognitive benefit in &#x003b5;4 carriers with greater n-3 levels, or less brain AD neuropathology with weekly seafood consumption.</p><p>In summary, these studies indicate an interaction between &#x0025b;4 allele and DHA efficacy, with the &#x0025b;4 allele potentially limiting the effectiveness of DHA supplementation on cognition later in the disease process. It would be important to assess the delivery of DHA to the brain by <italic>APOE</italic> &#x003b5;4 status before the onset of detectable brain amyloidosis and AD. These studies would then clarify whether cognitively healthy younger <italic>APOE</italic> &#x003b5;4 carriers have a chronic defect in DHA brain delivery years before the onset of neurodegeneration, presenting with an opportunity for DHA supplementation to prevent or slow the progression of AD.</p></sec><sec id="Sec7"><title>Conclusions</title><p>To our knowledge, this is the first study to demonstrate changes in CSF DHA levels in relation to <italic>APOE</italic> genotypes and CSF A&#x003b2;42 peptide levels. Our main finding suggests decreased DHA delivery to CSF in participants with lower CSF A&#x003b2;42 peptide and in carriers of the <italic>APOE</italic> &#x003b5;4 allele. These findings can help explain the lack of efficacy of DHA in participants with established AD. Future studies are needed to clarify if differences in DHA transport in participants carrying the <italic>APOE</italic> &#x003b5;4 allele appear earlier in life, before the onset of cognitive decline.</p></sec><sec id="Sec8"><title>Abbreviations</title><p>AA, arachidonic acid; A&#x003b2;42, amyloid-&#x003b2;42; AD, Alzheimer&#x02019;s disease; ADAS-cog, Alzheimer&#x02019;s Disease Assessment Scale-Cognition; ADCS, Alzheimer&#x02019;s Disease Cooperative Study; <italic>APOE</italic>, apolipoprotein E; cPLA<sub>2</sub>, calcium-dependent phospholipase A<sub>2</sub>; CSF, cerebrospinal fluid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; MMSE, Mini Mental State Examination; n-3 PUFA, &#x003c9;-3 polyunsaturated fatty acid; PLA<sub>2</sub>, phospholipase A<sub>2</sub>; p-Tau, phosphorylated Tau; Tg, transgenic</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Dr. Rema Raman, Karin Ernstrom, and the ADCS DHA Coordinating Center for facilitating access to the data.</p><sec id="FPar1"><title>Funding</title><p>HNY was supported by grant K23HL107389 from National Heart, Lung, and Blood Institute and grant NIRG-15-361854 from the Alzheimer&#x02019;s Association. ADRC project P50-AG05142-31 (to HCC) from the National Institute of Aging supported this project. This study was supported by grant U01 AG10483 from the National Institute on Aging. The placebo and DHA study drugs were provided by DSM. DSM also provided plasma and cerebrospinal fluid measurements of fatty acids.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The supporting data are available at the ADCS website and can be accessed by request: <ext-link ext-link-type="uri" xlink:href="http://www.adcs.org/Admin/dataCore.aspx">http://www.adcs.org/Admin/dataCore.aspx</ext-link></p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>HNY conceived of the CSF study design by <italic>APOE</italic> genotype. HNY and LSS designed the study analysis plan. HNY and WJM analyzed the data. HNY drafted the manuscript. JFQ, PSA, and KYM designed the original DHA trial. EBH analyzed the lipids in plasma and CSF. EBH, PSA, WJM, VR, JFQ, and HCC critically appraised the literature, and participated in the study design and writing the manuscript. JFQ, KYM, VR, HCC, and LSS critically appraised the manuscript for important intellectual content. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>KYM and EBH reported being employees of DSM Nutritional Products, a manufacturer of docosahexaenoic acid (DHA). JFQ and PSA reported being named as coinventors on a patent for DHA for the treatment of Alzheimer&#x02019;s disease in apolipoprotein E &#x003b5;4-negative individuals, which was filed in July 2009 with KYM as the inventor. Data lock for this trial was completed June 2009; the primary analysis was completed and the results presented in July 2009; and the patent was filed by Martek Biosciences (now part of DSM) in July 2009. JFQ and PSA were added as coinventors in February 2010. JFQ and PSA have waived personal rights to royalties related to this patent. None of the other authors reported financial disclosures. No nonfinancial conflicts of interest exist for any of the authors.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>Written informed consent was obtained from study participants, their legally authorized representatives, or both, according to local guidelines. The list of the participating sites can be found at <ext-link ext-link-type="uri" xlink:href="http://www.adcs.org">http://www.adcs.org</ext-link>.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x02019;s disease</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><issue>12</issue><fpage>1452</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ng.2802</pub-id><pub-id pub-id-type="pmid">24162737</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corder</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x02019;s disease in late onset families</article-title><source>Science</source><year>1993</year><volume>261</volume><issue>5123</issue><fpage>921</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1126/science.8346443</pub-id><pub-id pub-id-type="pmid">8346443</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genin</surname><given-names>E</given-names></name><etal/></person-group><article-title><italic>APOE</italic> and Alzheimer disease: a major gene with semi-dominant inheritance</article-title><source>Mol Psychiatry</source><year>2011</year><volume>16</volume><issue>9</issue><fpage>903</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.52</pub-id><pub-id pub-id-type="pmid">21556001</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunnane</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Fish, docosahexaenoic acid and Alzheimer&#x02019;s disease</article-title><source>Prog Lipid Res</source><year>2009</year><volume>48</volume><issue>5</issue><fpage>239</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2009.04.001</pub-id><pub-id pub-id-type="pmid">19362576</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunnane</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>29</volume><issue>3</issue><fpage>691</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22466064</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f6;derberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fatty acid composition of brain phospholipids in aging and in Alzheimer&#x02019;s disease</article-title><source>Lipids</source><year>1991</year><volume>26</volume><issue>6</issue><fpage>421</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF02536067</pub-id><pub-id pub-id-type="pmid">1881238</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrigan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer&#x02019;s disease patients and its relationship to acetyl CoA content</article-title><source>Int J Biochem Cell Biol</source><year>1998</year><volume>30</volume><issue>2</issue><fpage>197</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(97)00125-8</pub-id><pub-id pub-id-type="pmid">9608673</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Regional membrane phospholipid alterations in Alzheimer&#x02019;s disease</article-title><source>Neurochem Res</source><year>1998</year><volume>23</volume><issue>1</issue><fpage>81</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1023/A:1022457605436</pub-id><pub-id pub-id-type="pmid">9482271</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freund-Levi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>&#x003c9;-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD Study: a randomized double-blind trial</article-title><source>Arch Neurol</source><year>2006</year><volume>63</volume><issue>10</issue><fpage>1402</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archneur.63.10.1402</pub-id><pub-id pub-id-type="pmid">17030655</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>CC</given-names></name><etal/></person-group><article-title>The effects of omega-3 fatty acids monotherapy in Alzheimer&#x02019;s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2008</year><volume>32</volume><issue>6</issue><fpage>1538</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.05.015</pub-id><pub-id pub-id-type="pmid">18573585</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women</article-title><source>Nutr Neurosci</source><year>2008</year><volume>11</volume><issue>2</issue><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1179/147683008X301450</pub-id><pub-id pub-id-type="pmid">18510807</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial</article-title><source>JAMA</source><year>2010</year><volume>304</volume><issue>17</issue><fpage>1903</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1510</pub-id><pub-id pub-id-type="pmid">21045096</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yurko-Mauro</surname><given-names>K</given-names></name><etal/></person-group><article-title>Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline</article-title><source>Alzheimers Dement</source><year>2010</year><volume>6</volume><issue>6</issue><fpage>456</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2010.01.013</pub-id><pub-id pub-id-type="pmid">20434961</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vellas</surname><given-names>B</given-names></name><etal/></person-group><article-title>MAPT study: a multidomain approach for preventing Alzheimer&#x02019;s disease: design and baseline data</article-title><source>J Prev Alzheimers Dis</source><year>2014</year><volume>1</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">26594639</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Rest</surname><given-names>O</given-names></name><etal/></person-group><article-title>Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial</article-title><source>Neurology</source><year>2008</year><volume>71</volume><issue>6</issue><fpage>430</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000324268.45138.86</pub-id><pub-id pub-id-type="pmid">18678826</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daiello</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Association of fish oil supplement use with preservation of brain volume and cognitive function</article-title><source>Alzheimers Dement</source><year>2015</year><volume>11</volume><issue>2</issue><fpage>226</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.02.005</pub-id><pub-id pub-id-type="pmid">24954371</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Benefits of fatty fish on dementia risk are stronger for those without <italic>APOE</italic> &#x003b5;4</article-title><source>Neurology</source><year>2005</year><volume>65</volume><issue>9</issue><fpage>1409</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000183148.34197.2e</pub-id><pub-id pub-id-type="pmid">16275829</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whalley</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>n-3 Fatty acid erythrocyte membrane content, <italic>APOE</italic> &#x003b5;4, and cognitive variation: an observational follow-up study in late adulthood</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><issue>2</issue><fpage>449</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">18258638</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazinet</surname><given-names>RP</given-names></name><name><surname>Lay&#x000e9;</surname><given-names>S</given-names></name></person-group><article-title>Polyunsaturated fatty acids and their metabolites in brain function and disease</article-title><source>Nat Rev Neurosci</source><year>2014</year><volume>15</volume><issue>12</issue><fpage>771</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nrn3820</pub-id><pub-id pub-id-type="pmid">25387473</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Reduction in DHA transport to the brain of mice expressing human <italic>APOE4</italic> compared to <italic>APOE2</italic></article-title><source>J Neurochem</source><year>2014</year><volume>129</volume><issue>3</issue><fpage>516</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/jnc.12640</pub-id><pub-id pub-id-type="pmid">24345162</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calon</surname><given-names>F</given-names></name></person-group><article-title>Omega-3 polyunsaturated fatty acids in Alzheimer&#x02019;s disease: key questions and partial answers</article-title><source>Curr Alzheimer Res</source><year>2011</year><volume>8</volume><issue>5</issue><fpage>470</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2174/156720511796391881</pub-id><pub-id pub-id-type="pmid">21605051</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freund-Levi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer&#x02019;s disease: the OmegAD study</article-title><source>J Intern Med</source><year>2014</year><volume>275</volume><issue>4</issue><fpage>428</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/joim.12166</pub-id><pub-id pub-id-type="pmid">24410954</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuratko</surname><given-names>CN</given-names></name><etal/></person-group><article-title>The relationship of docosahexaenoic acid (DHA) with learning and behavior in healthy children: a review</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><issue>7</issue><fpage>2777</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.3390/nu5072777</pub-id><pub-id pub-id-type="pmid">23877090</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arterburn</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food</article-title><source>Lipids</source><year>2007</year><volume>42</volume><issue>11</issue><fpage>1011</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s11745-007-3098-5</pub-id><pub-id pub-id-type="pmid">17713804</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folch</surname><given-names>J</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>Sloane-Stanley</surname><given-names>G</given-names></name></person-group><article-title>A simple method for the isolation and purification of total lipids from animal tissues</article-title><source>J Biol Chem</source><year>1957</year><volume>226</volume><issue>1</issue><fpage>497</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">13428781</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>WR</given-names></name><name><surname>Smith</surname><given-names>LM</given-names></name></person-group><article-title>Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol</article-title><source>J Lipid Res</source><year>1964</year><volume>5</volume><issue>4</issue><fpage>600</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14221106</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid biomarker signature in Alzheimer&#x02019;s disease neuroimaging initiative subjects</article-title><source>Ann Neurol</source><year>2009</year><volume>65</volume><issue>4</issue><fpage>403</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/ana.21610</pub-id><pub-id pub-id-type="pmid">19296504</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>G</given-names></name><etal/></person-group><article-title>Imaging neuroinflammation in Alzheimer&#x02019;s disease with radiolabeled arachidonic acid and PET</article-title><source>J Nucl Med</source><year>2008</year><volume>49</volume><issue>9</issue><fpage>1414</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2967/jnumed.107.049619</pub-id><pub-id pub-id-type="pmid">18703605</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazan</surname><given-names>NG</given-names></name><name><surname>Colangelo</surname><given-names>V</given-names></name><name><surname>Lukiw</surname><given-names>WJ</given-names></name></person-group><article-title>Prostaglandins and other lipid mediators in Alzheimer&#x02019;s disease</article-title><source>Prostaglandins Other Lipid Mediat</source><year>2002</year><volume>68</volume><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/S0090-6980(02)00031-X</pub-id><pub-id pub-id-type="pmid">12432919</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashek</surname><given-names>DG</given-names></name><name><surname>Coleman</surname><given-names>RA</given-names></name></person-group><article-title>Cellular fatty acid uptake: the contribution of metabolism</article-title><source>Curr Opin Lipidol</source><year>2006</year><volume>17</volume><issue>3</issue><fpage>274</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/01.mol.0000226119.20307.2b</pub-id><pub-id pub-id-type="pmid">16680032</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuipers</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2012</year><volume>86</volume><issue>1</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2011.10.012</pub-id><pub-id pub-id-type="pmid">22115845</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carver</surname><given-names>JD</given-names></name><etal/></person-group><article-title>The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects</article-title><source>Brain Res Bull</source><year>2001</year><volume>56</volume><issue>2</issue><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0361-9230(01)00551-2</pub-id><pub-id pub-id-type="pmid">11704343</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purdon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Energy consumption by phospholipid metabolism in mammalian brain</article-title><source>Neurochem Res</source><year>2002</year><volume>27</volume><issue>12</issue><fpage>1641</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1023/A:1021635027211</pub-id><pub-id pub-id-type="pmid">12515317</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonteh</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer&#x02019;s disease</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>e100519</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0100519</pub-id><pub-id pub-id-type="pmid">24956173</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palop</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x02019;s disease</article-title><source>Neuron</source><year>2007</year><volume>55</volume><issue>5</issue><fpage>697</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.07.025</pub-id><pub-id pub-id-type="pmid">17785178</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Mejia</surname><given-names>RO</given-names></name><etal/></person-group><article-title>Phospholipase A<sub>2</sub> reduction ameliorates cognitive deficits in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Nat Neurosci</source><year>2008</year><volume>11</volume><issue>11</issue><fpage>1311</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nn.2213</pub-id><pub-id pub-id-type="pmid">18931664</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtonen</surname><given-names>JY</given-names></name><name><surname>Holopainen</surname><given-names>JM</given-names></name><name><surname>Kinnunen</surname><given-names>PK</given-names></name></person-group><article-title>Activation of phospholipase A<sub>2</sub> by amyloid &#x003b2;-peptides in vitro</article-title><source>Biochemistry</source><year>1996</year><volume>35</volume><issue>29</issue><fpage>9407</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1021/bi960148o</pub-id><pub-id pub-id-type="pmid">8755719</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>SI</given-names></name></person-group><article-title>Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo</article-title><source>Prostaglandins Leukot Essent Fatty Acids</source><year>2013</year><volume>88</volume><issue>1</issue><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2012.05.003</pub-id><pub-id pub-id-type="pmid">22766388</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function</article-title><source>J Neurochem</source><year>2009</year><volume>111</volume><issue>2</issue><fpage>510</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06335.x</pub-id><pub-id pub-id-type="pmid">19682204</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plourde</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE &#x003b5;4 but not by the common PPAR-&#x003b1; L162V polymorphism in men</article-title><source>Br J Nutr</source><year>2009</year><volume>102</volume><issue>8</issue><fpage>1121</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1017/S000711450938215X</pub-id><pub-id pub-id-type="pmid">19828088</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>V</given-names></name><etal/></person-group><article-title>Postprandial enrichment of triacylglycerol-rich lipoproteins with omega-3 fatty acids: lack of an interaction with apolipoprotein E genotype?</article-title><source>Lipids Health Dis</source><year>2014</year><volume>13</volume><fpage>148</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-13-148</pub-id><pub-id pub-id-type="pmid">25227179</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samieri</surname><given-names>C</given-names></name><etal/></person-group><article-title>Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype</article-title><source>J Lipid Res</source><year>2013</year><volume>54</volume><issue>9</issue><fpage>2559</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1194/jlr.P036475</pub-id><pub-id pub-id-type="pmid">23801662</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samieri</surname><given-names>C</given-names></name><etal/></person-group><article-title>&#x003c9;-3 fatty acids and cognitive decline: modulation by ApoE&#x003b5;4 allele and depression</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><issue>12</issue><fpage>2317</fpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.03.020</pub-id><pub-id pub-id-type="pmid">20570406</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease</article-title><source>Arch Neurol</source><year>2003</year><volume>60</volume><issue>7</issue><fpage>940</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/archneur.60.7.940</pub-id><pub-id pub-id-type="pmid">12873849</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Association of seafood consumption, brain mercury level, and <italic>APOE &#x003b5;4</italic> status with brain neuropathology in older adults</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>5</issue><fpage>489</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.19451</pub-id><pub-id pub-id-type="pmid">26836731</pub-id></element-citation></ref></ref-list></back></article>